Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice

Gene Therapy

Volumn 16, Issue 10, 2009, Pages 1234-1244

  Hwang, D H ^a,b   Lee, H J ^b,c   Park, I H ^c   Seok, J I ^a   Kim, B G ^a   Joo, I S ^a   Kim, S U ^b,c  

^a Ajou University School of Medicine   (South Korea)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Chung Ang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR HORN CELL; ARTICLE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL MIGRATION; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; DRUG ADMINISTRATION ROUTE; DRUG MECHANISM; GENE OVEREXPRESSION; GRAY MATTER; HUMAN; HUMAN CELL; LIFE EXTENSION; MOUSE; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; SPINAL CORD; SPINAL CORD DISEASE; SURVIVAL TIME; TRANSGENIC MOUSE; TREATMENT RESPONSE; UPREGULATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; GRAFT SURVIVAL; HUMANS; INJECTIONS, SPINAL; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MOTOR ACTIVITY; MOTOR NEURONS; NEURONS; SPINAL CORD; STEM CELL TRANSPLANTATION; STEM CELLS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; MUS;

EID: 70350167840     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.80     Document Type: Article

References (55)

1. Rowland LP. Natural history and clinical features of amyotrophic lateral sclerosis and related motor neuron disease. In: Calne DB (ed). Neurodegenerative Diseases. W.B. Saunders: Philadelphia, 1994, pp 507-522.
2. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-1700.
3. Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiat 2005; 76: 1046-1057.
4. Hudson AJ. Amyotrophic lateral sclerosis: Clinical evidence for difference in pathogenesis and etiology. In: Hudson AJ (ed). Amyotrophic Lateral Sclerosis-Concepts in Pathogenesis and Etiology. University of Toronto Press: Toronto, 1999, pp 108-143.
5. Swash M. Stem cell therapy in human ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 133-134.
6. Silani V, Cova L, Corbo M, Ciammola A, Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet 2004; 364: 200-202.
7. Lindvall O, KoKaia Z. Stem cells for the treatment of neurological disorders. Nature 2006; 441: 1094-1096.
8. Wichterle H, Lieberam I, Porter JA, Jessel TM. Directed differentiation of embryonic stem cells into motor neurons. Cell 2002; 110: 385-397.
9. Miles GB, Yohn DC, Wichterle H, Jessel TM, Rafuse VF, Brownstone RM. Functional properties of motoenrons derived from mouse embryonic stem cells. J Neurosci 2002; 24: 7848-7858.
10. Harper JM, Krishnan C, Darman JS, Deshpande DM, Peck S, Shats I et al Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motorneuron-injured adult rats. Proc Natl Acad Sci USA 2004; 101: 7123-7128.
11. Li P, Tessler A, Han SS, Fischer I, Rao MS, Selzer ME. Fate of immortalized human neuronal progenitor cells transplanted in rat spinal cord. Arch Neurol 2005; 62: 223-229.
12. Kerr DA, Llad J, Shamblott MJ, Maragakis NJ, Irani DN, Crawford TO et al. Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J Neurosci 2003; 23 5131-5140.
13. Corti S, Locatelli F, Papadimitriou D, Del Bo R, Nizzardo M, Nardini M et al. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. Brain 2007; 130: 1289-1305.
14. Tolosa L, Mir M, Asensio VJ, Olmos G, Llado J. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem 2008; 105: 1080-1090.
15. Tovar LB, Zepeda A, Tapia R. Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration. J Neuropathol Exp Neurol 22007; 66: 913-922.
16. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 204; 429: 413-417.
17. Zheng C, Nennesmo I, Fadeel B, Henter JI. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2004; 56: 564-567.
18. Storkebaum E, Lambrechts D, Dewerchin M, Moreno MP, Appelmans S, Oh H et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8: 85-92.
19. Wang Y, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci 2007; 27: 304-307.
20. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
21. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
22. Parenti A, Bellik L, Brogelli L, Filippi S, Ledda F. Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004; 286: H1978-H1984.
23. Crottogini A, Meckert PC, Vera Janavel G, Lascano E, Negroni J, Del Valle H et al. Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. Hum Gene Ther 2003; 14: 1307-1318.
24. Kang YH, Berthiaume F, Nath BD, Yarmush ML. Growth factors and nonparenchymal cell conditioned media induce mitogenic responses in stable long-term adult rat hepatocyte cultures. Exp Cell Res 2004; 293: 239-247.
25. Laguens R, Cabeza Meckert P, Vera Janavel G, Del Valle H, Lascano E, Negroni J et al. Entrance in mitosis of adult cardiomyocytes in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer. Gene Therapy 2002; 9: 1676-1681.
26. Vera Janavel G, Crottogini A, Cabeza Meckert P, Cuniberti L, Mele A, Papouchado M et al. Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep. Gene Therapy 2006; 13: 1133-1142.
27. Stockebaum E, Lambrechts D, Cameliet P. VEGF: Once regardes as a specific angiogenetic factor, now implicated in neuroprotection. Bioessaeys 2004; 26: 943-954.
28. Lee HJ, Kim KS, Park IH, Kim SU. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE 2007; 2(e156): 1-14.
29. Li B, Xu W, Luo C, Gozal D, Liu R. VEGF-induced activation of the PI3-K/ Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res 2003; 111: 155-164.
30. Dewil M, Lambrechts D, Sciot R, Shaw PJ, Ince PG, Robberecht W et al Vascular endothelial growth factor counteracts the loss of phospho-Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis. Neuropathol appl neurobiol 2007; 33: 499-509.
31. Lu L, Zheng L, Viera L, Suswam E, Li Y, Li X et al. Mutant Cu/ Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J Neurosci 2007; 27: 7929-7938.
32. Devos D, Morea C, Lassalle P, Perez T, De Seze J, Brunaud-Danel V et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004; 62: 2127-2129.
33. Izecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotro/rophic lateral sclerosis. Clin Neurol Neurosurg 2004; 106: 135-138.
34. Nagata T, Nagano I, Shiote M, Narai H, Murakami T, Hayashi T et al Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res 2007; 29: 772-776.
35. Mitsumoto H, Gordon P, Kaufmann P, Gooch CL, Przedborski S, Rowland LP. Randomized control trials in ALS: Lessons learned. Amyotroph Lat Scler Other Motor Neuron Disord 2004; 5(Suppl. 1): 8-13.
36. Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin Pharmacokinet 2001; 40: 907-946.
37. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001; 28: 131-138.
38. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383-394.
39. Brockington A, Wharton SB, Fernando M, Gelsthorpe CH, Baxter L, Ince PG et al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropath Exp Neurol 2006; 65: 26-36.
40. Federici T, Boulis NM. Gene-based treatment of motor neuron diseases. Muscle Nerve 2006; 33: 302-323.
41. Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 2005; 16: 509-521.
42. Watabe K, Ohashi T, Sakamoto T, Kawazoe Y, Takeshima T, Oyanagi K et al. Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor. J Neurosci Res 2000; 60: 511-519.
43. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-842.
44. Svendsen CN, Langston JW. Stem cells for Parkinson disease and ALS: replacement or protection? Nat Med 2004; 10: 224-225.
45. Jeong SW, Chu K, Jung KH, Lee ST, Kim M et al. Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke 2003; 34: 2258-2263.
46. Lee HJ, Kim KS, Kim EJ, Choi HB, Lee KH, Park IH et al. Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells 2007; 25: 1204-1212.
47. Kim BG, Hwang DH, Kim EJ, Lee SI, Kim SU. Stem cell-based therapy in spinal cord injury. Cell Transplant 2007; 16: 355-364.
48. Kim SU, Park IH, Kim TH, Kim KS, Choi HB, Hong SH et al. Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology 2006; 26: 129-140.
49. Ryu JK, Kim J, Cho SJ, Hatori K, Nagai A, Choi HB et al. Proactive transplantation of human neural stem cells blocks neuronal cell death in rat model of Huntington disease. Neurobiol Disease 2004; 16: 68-77.
50. Meng X, Shen J, Ohashi T, Maeda H, Kim SU, Eto E. Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J Neurosci Res 2003; 74: 266-277.
51. Chao MV. Neurotrophins and their recptors: A convergence point for many signalling pathways. Nat Rev Neurosci 2003; 4: 299-309.
52. Fagan SC, Hess DC, Hohnadel EJ, Pollock DM, Ergul A. Targets for vascular protection after acute ischemic stroke. Stroke 2004; 35: 2220-2225.
53. Kim SU. Human neural stem cells genetically modified for brain repair in neurological diseases. Neuropathology 2004; 24: 159-171.
54. Hylden JL, Wilcox GL. Intrathecal morphine in mice: A new technique. Eur J Pharmacol 1980; 67: 313-316.
55. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991; 231: 482-497.